ClinicalTrials.gov

Key Record Dates

ClinicalTrials.gov Identifier: NCT02224781
Brief Title: Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

First Submitted : August 22, 2014
First Submitted that Met QC Criteria : August 22, 2014
First Posted : August 25, 2014 (Estimate)

Last Update Submitted that Met QC Criteria : November 5, 2018
Last Update Posted : November 6, 2018